Esketamine DPI - low dose

DRUG2 trials

Sponsors

Celon Pharma SA

Conditions

Bipolar DepressionMajor Depressive Disorder

Phase 2

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

CompletedNCT03965871

Celon Pharma SABipolar Depression

Start: 2019-03-28End: 2021-02-19Updated: 2021-03-19

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

CompletedNCT03965858

Celon Pharma SAMajor Depressive Disorder

Start: 2019-02-25End: 2020-04-24Updated: 2020-04-28